In Brief: Schering's Claritin-D
This article was originally published in The Tan Sheet
Schering's Claritin-D: FDA approves a 24-hour extended-release tablet formulation Aug. 23. The company plans to launch the once-daily Rx antihistamine/decongestant combo (10 mg loratadine, 240 mg pseudoephedrine) in early September at an average wholesale price of $2.28 per day, equivalent to the price of a day's therapy with twice-daily Claritin-D. Claritin (loratadine) has been available since April 1993 and is the top-selling antihistamine in the U.S. It continues to show strong growth, with a gain of 38% to $347 mil. for the second quarter. Claritin-D 12-hour extended-release (5 mg loratadine, 120 mg pseudoephedrine) was approved in November 1994...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC